Cellebrite DI (CLBT) to Release Earnings on Thursday

Key Points

• Cellebrite DI will release Q1 2026 results before the market opens on Thursday, May 14, 2026, with analysts expecting EPS $0.0538 and revenue $127.014M; the earnings call is scheduled for 8:30 AM ET.
• In the prior quarter (reported Feb. 11) CLBT posted $0.14 EPS and $128.82M revenue (up 28.8% year-over-year); analysts now expect $0 EPS for the current fiscal year and $1 EPS next year, with a consensus price target of $22.50 and an overall "Moderate Buy" rating.
• Shares opened at $13.17 (down 3.1%), giving a market cap of $3.29B and a P/E of 42.48, with a 52-week range of $11.02–$20.45, and institutional investors owning about 45.88% of the stock.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) is projected to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Cellebrite DI to post earnings of $0.0538 per share and revenue of $127.0140 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. The company had revenue of $128.82 million for the quarter, compared to analysts' expectations of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm's revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the firm earned $0.10 EPS. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Cellebrite DI Stock Down 3.1%

Shares of NASDAQ CLBT opened at $13.17 on Thursday. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 2.08 and a beta of 1.15. The stock's fifty day simple moving average is $13.61 and its 200 day simple moving average is $15.77. Cellebrite DI has a 52-week low of $11.02 and a 52-week high of $20.45.

Wall Street Analysts Forecast Growth

CLBT has been the topic of a number of recent research reports. Wall Street Zen upgraded Cellebrite DI from a "sell" rating to a "hold" rating in a report on Sunday, March 15th. Needham & Company LLC decreased their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Cellebrite DI presently has an average rating of "Moderate Buy" and a consensus price target of $22.50.

Institutional Trading of Cellebrite DI

Several hedge funds and other institutional investors have recently modified their holdings of the business. Mangrove Partners IM LLC acquired a new stake in Cellebrite DI during the fourth quarter valued at $230,000. Virtus Advisers LLC boosted its position in Cellebrite DI by 297.7% during the third quarter. Virtus Advisers LLC now owns 12,954 shares of the company's stock valued at $240,000 after purchasing an additional 9,697 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in Cellebrite DI during the third quarter valued at $386,000. Amundi acquired a new stake in Cellebrite DI during the third quarter valued at $264,000. Finally, SkyView Investment Advisors LLC boosted its position in Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock valued at $597,000 after purchasing an additional 970 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.